XNW4107

DRUG3 trials

Sponsors

Evopoint Biosciences USA Inc., Evopoint Biosciences Inc.

Conditions

Bacterial InfectionsHospital-acquired bacterial pneumonia (HABP)including ventilated HABP (vHABP) and ventilator-associated bacterial pneumonia (VABP) caused by Gram-negative bacteria

Phase 1

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

CompletedNCT04482569

Evopoint Biosciences Inc.Bacterial Infections

Start: 2020-07-10End: 2021-09-30Updated: 2023-02-16

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

CompletedNCT04801043

Evopoint Biosciences Inc.Bacterial Infections

Start: 2021-03-02End: 2022-01-31Updated: 2023-02-16

Phase 3

A Multicenter, Randomized, Double-Blind, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin-XNW4107 in Comparison with Imipenem/Cilastatin/Relebactam in Adults with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia

CompletedCTIS2022-501952-27-00

Evopoint Biosciences USA Inc.Hospital-acquired bacterial pneumonia (HABP), including ventilated HABP (vHABP) and ventilator-associated bacterial pneumonia (VABP) caused by Gram-negative bacteria

Start: 2024-04-19End: 2024-07-26Target: 58Updated: 2024-08-21